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Abstract
Purpose Foregut carcinoid tumours have a different em-
bryological origin than other gastroenteropancreatic neuro-
endocrine tumours (GEP NETs). In the total group of GEP
NETs (n=131), treatment with 177Lu-octreotate resulted in
tumour remission in 47% of patients, with a median time to
progression (TTP) of >36 months. As patients with foregut
carcinoids may respond differently, we here present the
effects of this treatment in a subgroup of patients with
foregut carcinoids of bronchial, gastric or thymic origin.
Methods Nine patients with bronchial, five with gastric and
two with thymic carcinoids were treated. All patients had
metastasised disease. The intended cumulative dose of
177Lu-octreotate was 22.2–29.6 GBq. Southwest Oncology
Group criteria were used for response evaluation.
Results Bronchial carcinoids: Five patients had partial
remission, one had minor response (MR, tumour size
reduction: ≥25%, <50%), two had stable disease (SD) and
one had progressive disease (PD). Median TTP was
31 months. Gastric carcinoids: One patient had complete
remission, one had MR and two had SD, including one with
PD at baseline. One patient developed PD. Thymic
carcinoids: One patient had SD. In the other patient,
disease remained progressive. All patients: Overall remis-
sion rate was 50%, including MR.
Conclusion 177Lu-octreotate treatment can be effective in
patients with bronchial and gastric carcinoids. Its role in
thymic carcinoids cannot be determined yet because of the
limited number of patients. The overall remission rate of
50% in patients with the studied foregut carcinoids is
comparable to that in the total group of GEP NETs.
Keywords 177Lu-octreotate . Foregut carcinoid . Bronchial
carcinoid . Gastric carcinoid . Thymic carcinoid
Introduction
Carcinoid tumours belong to the group of gastroentero-
pancreatic neuroendocrine tumours (GEP NETs). These
tumours often express somatostatin receptor subtype 2,
which can be visualised with 111In-octreotide scintigraphy
(somatostatin receptor scintigraphy, SRS) [1]. If SRS is
positive, peptide receptor radionuclide therapy with radio-
labelled somatostatin analogues, e.g. [177Lu-DOTA0,Tyr3]
octreotate (177Lu-octreotate) may be used in treating
patients with GEP NETs. According to their origin,
carcinoid tumours can be subdivided into three groups
[2]: foregut, midgut and hindgut carcinoids. Foregut
carcinoid tumours are derived from neuroendocrine cells
of the embryologically most proximal part of the gut (from
sinuses to duodenum), including lungs, thymus, pancreas
and gall bladder. The most common forms of foregut
carcinoids are of bronchial and gastric origin: approximate-
ly 24% of all carcinoids arise from lung and 6% from
stomach. Carcinoids of thymic origin are very rare (less
than 1% of all carcinoids) [3].
In 2000, the World Health Organisation (WHO) intro-
duced a revised clinicopathological classification of GEP
Eur J Nucl Med Mol Imaging (2007) 34:1219–1227
DOI 10.1007/s00259-006-0355-4
M. van Essen (*) : E. P. Krenning :W. H. Bakker :
D. J. Kwekkeboom
Department of Nuclear Medicine, Erasmus MC,
Dr. Molewaterplein 40,
3015 GD Rotterdam, The Netherlands
e-mail: m.vanessen@erasmusmc.nl
E. P. Krenning :W. W. de Herder :M. O. van Aken
Department of Internal Medicine, Erasmus MC,
Rotterdam, The Netherlands
NETs [4]. In this classification, carcinoid is no longer
mentioned. A distinction is made between well-differentiat-
ed neuroendocrine tumours, well-differentiated neuroendo-
crine carcinomas and poorly differentiated neuroendocrine
carcinomas, with the origin of the tumour and the clinical
syndrome added. However, the term “carcinoid” is still used
frequently in clinical practice. Yet in the WHO classification
of lung tumours of 1999, bronchial carcinoid tumours are
still mentioned as a subgroup of epithelial lung tumours [5].
Carcinoid tumours account for at least 0.4% of lung
tumours in epidemiological studies [6] and up to 5% in
surgical series [7]. Based on histology, bronchial carcinoids
can be classified in two groups: typical (around 85%) and
atypical (around 15%) [8]. This classification has prognos-
tic consequences: 5-year survival in patients with typical
bronchial carcinoids was found to be 90%, compared with
69% in those with atypical bronchial carcinoids [8].
Diarrhoea and cutaneous flushing (carcinoid syndrome)
occur in around 8% of patients with bronchial carcinoids.
About 6% of bronchial carcinoids produce adrenocortico-
tropic hormone (ACTH) and as a result cause Cushing’s
syndrome [8].
Gastric carcinoids are classified into three groups [9].
Type 1 gastric carcinoid is the most common (70–80% of
all gastric carcinoids) and is associated with chronic
atrophic gastritis. Gastric acid production is absent and
serum gastrin levels are elevated. Its metastatic potential is
less than 5%. Type 2 gastric carcinoid is less common (5–
10%) and is associated with high serum gastrin levels due
to gastrinomas as part of multiple endocrine neoplasia-1
(MEN-1) syndrome with consequent high gastric acid
production. Metastases develop in 7–12%. Type 3 gastric
carcinoids are not associated with any other medical
condition and therefore are called sporadic gastric carci-
noids. Sporadic gastric carcinoids have a risk of metasta-
sising of 50–100%. [see 10 and 11 for a review and
references within].
Thymic carcinoids can occur sporadically or as part of
MEN-1 syndrome and occur more frequently in male than in
female patients [12]. Thymic carcinoids metastasise
frequently or are often inoperable because of locoregional
infiltrative growth. A study by Fukai et al. reported that in 10
out of 13 patients distant metastases developed after total
resection of the primary tumour and local lymph node
metastases, some as late as 8 years postoperatively [13].
Carcinoid syndrome in patients with thymic carcinoid occurs
very rarely (less than 1%), whereas ectopic Cushing’s
syndrome occurs in up to 17% [12].
Currently the radiolabelled somatostatin analogue 177Lu-
octreotate is administered in our hospital when treating
patients with somatostatin receptor subtype 2-positive
tumours. This treatment results in tumour size reduction
in 47% in patients from the total group of GEP NETs,
including 19% minor response (MR, tumour size reduction
≥25%, <50%) [14]. Because of their different embryolog-
ical origin, the present study was performed to evaluate
whether foregut carcinoid tumours of bronchial, gastric and
thymic origin respond differently to treatment with 177Lu-
octreotate in comparison with the total group of GEP NETs.
Materials and methods
Patients
The study population comprised nine patients with metas-
tasised bronchial carcinoids, five with metastasised gastric
carcinoids and two with metastasised thymic carcinoids. No
patients with carcinoid tumours of certain duodenal or
pancreatic origin were referred for treatment. Patients were
consecutively referred to our hospital. All patients had
measurable disease. All patients had tumour tissue uptake
with [111In-DTPA0]octreotide scintgraphy (OctreoScan®)
that was on average higher than uptake in normal hepatic
tissue on planar images. Patients with known somatostatin
receptor-negative lesions were excluded. Patients had not
been treated with other radiolabelled somatostatin ana-
logues before. Prerequisites for treatment were haemoglo-
bin (Hb) ≥5.5 mmol/l, WBC≥2·109/l, platelets≥80·109 /l,
creatinine≤150 μmol/l and creatinine clearance ≥40 ml/min,
and Karnofsky performance score (KPS) ≥50. All patients
gave written informed consent to participation in the study,
which was approved by the medical ethical committee of the
hospital.
Methods
[DOTA0,Tyr3]octreotate was obtained from Mallinckrodt
(St Louis, MO, USA). 177LuCl3 was obtained from NRG
(Petten, the Netherlands) and Missouri University Research
Reactor (Columbia, MO, USA) and was distributed by
IDB-Holland (Baarle-Nassau, the Netherlands). 177Lu-
octreotate was locally prepared as described previously
[15].
Granisetron 3 mg was injected intravenously, as a
precaution against nausea. In order to reduce radiation dose
to the kidneys, an infusion of amino acids (arginine 2.5%
and lysine 2.5%) was started 30 min before the adminis-
tration of the radiopharmaceutical and lasted 4 h. Via a
second pump system, the radiopharmaceutical was co-
administered. Cycle doses were 7.4 GBq, injected in
30 min. The interval between treatments was 6–10 weeks.
Patients were treated up to an intended cumulative dose of
22.2–29.6 GBq; if dosimetric calculations done on post-
therapy scans indicated that the radiation dose to the
kidneys would exceed 23 Gy with a dose of 29.6 GBq,
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the cumulative dose was reduced to 22.2–27.8 GBq. The
dose of the last cycle was then adjusted to 3.7 or 5.55 GBq,
administered in 30 min as well.
Routine haematology, liver and kidney function tests,
and hormone measurements were performed before each
therapy, as well as with follow-up visits. Computed
tomography (CT) or magnetic resonance imaging (MRI)
was performed within 3 months before the first therapy, and
6–8 weeks, 3 months and 6 months after the last treatment,
and thereafter every 6 months.
Imaging
Planar spot images of the upper abdomen and other regions
with somatostatin receptor-positive pathology were
obtained 24 h after injection of the therapeutic dose of
177Lu-octreotate. Upper abdominal images were also
obtained on day 3 or 4 and day 7 or 8 for kidney dosimetry.
Counts (20% window) from the 208-keV γ peak were
collected. The acquisition time was 7.5 min.
In vivo measurements
The tumours on CT or MRI were measured and scored
according to modified Southwest Oncology Group
(SWOG) solid tumour response criteria [16]. MR was
defined as a tumour size reduction of ≥25% and <50%. MR
was added since GEP NETs in general are slow-growing
tumours and can be cystic, which makes it unlikely that
they respond similarly to treatment as fast-growing solid
tumours.
The uptake during pre-treatment [111In-DTPA0]octreo-
tide scintigraphy was scored visually on planar images
using the following four-point scale: lower than (grade 1),
equal to (grade 2), or higher than (grade 3) normal liver
tissue, or higher than normal spleen or kidney uptake
(grade 4).
Statistics
Kaplan-Meier survival analysis was used to estimate
median time to progression (TTP) in the group of patients
with bronchial carcinoids. Fisher’s exact test or Pearson χ2
test was used to evaluate differences in frequencies of
characteristics or responses between groups. P values of
<0.05 were considered statistically significant.
Results
Baseline patient characteristics per disease are presented in
Table 1. Sixteen patients were included. Age ranged from
37 to 76 years (median 57 years) and Karnofsky perfor-
mance status (KPS) at entry ranged from 70 to 100 (median
90). All patients had metastasised disease. In five patients
(31%), progression of disease was documented on CT or
MRI in the 12 months before starting 177Lu-octreotate.
177Lu-octreotate was the first therapy to be given in three
Table 1 Patient characteristics
at baseline
PD progressive disease, SD
stable disease
a Four typical bronchial carci-
noids, five atypical bronchial
carcinoids
b Progression documented in
12 months before treatment
Disease Bronchial carcinoid Gastric carcinoid Thymic carcinoid
Total no. of patients 9a 5 2
Sex
M/F 6/3 2/3 2/−
Age, years
Median (range) 62 (37–75) 50 (47–76) 53 (40–65)
KPS
Median (range) 90 (80–100) 90 (70–100) 90 (90)
Hormonal syndrome
Carcinoid syndrome 2 – –
Cushing’s syndrome – – 1
Uptake of OctreoScan
Grade 3 8 5 2
Grade 4 1 – –
Tumour status at baseline
PDb 2 2 1
SD 2 1 –
Unknown 5 2 1
Prior therapies
None – 2 1
Surgery 8 3 –
Chemotherapy 1 2 1
Radiotherapy 2 – 1
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patients. Fifteen patients (94%) had grade 3 uptake on pre-
therapy SRS and one patient (6%) had grade 4 uptake. In
the total group of GEP NETs, 3% had grade 2 uptake, 78%
had grade 3 uptake and 19% had grade 4 uptake [14]. This
difference was not statistically significant (Fisher’s exact
test, p>0.05).
Frequencies of several predictive factors for progressive
disease as treatment outcome that were significant for the
whole group of GEP NETs are presented in Table 2 for
patients with foregut carcinoids and for patients from the
total group of GEP NETs [14]. None of the differences was
statistically significant (Fisher’s exact test or Pearson χ2
test).
WHO grade 3 haematological toxicity occurred in three
patients. Grade 4 haematological toxicity did not occur.
Patients reported nausea after 25% of administrations.
Although nausea was mostly mild, vomiting occurred in
12% of all administrations. Four patients reported pain in
tumour-involved regions (i.e. in 10% of all administra-
tions). Seventy-five percent of patients had mild hair loss
after the treatment. No alopecia was reported.
Nine patients with bronchial carcinoids were treated. In
two patients, metastases were present in the chest only. All
other patients had distant metastases. None of the patients
had other neuroendocrine tumours consistent with a MEN
syndrome. Two patients had proven progressive disease
(PD) in the 12 months before starting treatment with 177Lu-
octreotate. Four patients had typical bronchial carcinoids
and five had atypical bronchial carcinoids. Two patients had
symptoms consistent with carcinoid syndrome. None of the
patients had symptoms, signs or biochemical abnormalities
indicating ectopic ACTH production. Two patients did not
achieve the intended cumulative dose: one because of
disease progression and the other because of persistent
myelosuppression. Five of nine patients (56%) had partial
remission (PR) (Fig. 1). One of nine patients had an MR.
Two patients had stable disease (SD) as treatment outcome.
In one patient with PD at baseline, disease remained
progressive and the intended cumulative dose was not
achieved. Treatment outcome is summarised in Fig. 2. Two
patients died, one 13 months and the other 15 months after
start of treatment with 177Lu-octreotate. Seven patients were
still alive after a median follow-up of 36 months (range 23–
74 months). To evaluate differences in treatment outcome
according to histological subtype, patients with proven
atypical carcinoids were compared with patients with
typical carcinoid. Four of five patients with atypical
carcinoids had remission (3 PR, 1 MR), compared with
two of the four patients with typical bronchial carcinoid (2
PR), (Fisher’s exact test, p>0.05). In the group of patients
with bronchial carcinoids, an estimation of median TTP
was made using a Kaplan-Meier curve. In four patients,
TTP was reached after 9, 13, 20 and 31 months. In four
patients, disease remained unchanged after 11, 21, 24 and
34 months’ follow-up. The estimated median TTP was
31 months.
177Lu-octreotate was administered to five patients with
gastric carcinoids. All patients had type 3 (sporadic) gastric
carcinoids and all had distant metastases. None of the
patients had symptoms due to the release of hormones. Two
patients had proven PD in the 12 months before starting
treatment. All patients achieved the intended cumulative
dose. One patient had complete remission (CR) of disease
(Fig. 3). Disease remained unchanged during the follow-up
of 11 months. One patient had MR, which remained
unchanged for 8 months’ follow-up. Two patients, includ-
ing one with PD at baseline, had SD. In the patient with PD
at baseline, TTP was 11 months. In the other patient,
disease was radiologically stable for 12 months’ follow-up,
but became clinically progressive after 16 months’ follow-
up. Finally, one patient developed PD despite the treatment
(Fig. 2). Estimated median TTP in this group was 16 months
(Kaplan-Meier curve, n=4, two censored patients). Three
patients died, respectively 6, 17 and 21 months after start of
treatment with 177Lu-octreotate. Two patients were still
alive after a follow-up of 18 and 21 months.
Two patients with thymic carcinoids were included in the
trial. Both were men. One patient had PD at baseline and
was also treated with 5-fluorouracil between the admin-
istrations of 177Lu-octreotate. Despite treatments, disease
Table 2 Baseline characteristics in respect of factors that predict
chances of tumour progression during treatment with 177Lu-octreotate
in patients from the total group of GEP NETs (n=125) and in patients




of GEP NETs [14]
p valuea
Tumour mass




None/moderate 81% 73% 0.56
Extensive 19% 27%
Weight loss
Absent 69% 82% 0.19
Present 31% 18%
KPS
>70 94% 83% 0.47
≤70 6% 17%
Tumour mass was judged on [111 In-DTPA0 ]octreotide scintigrams,
and liver involvement was judged on CT/MRI. Weight loss was
scored positive if it at least amounted to 1 kg per month, existing for
at least 3 months
KPS Karnofsky performance score
a Fisher’s exact test or Pearson χ2 test
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remained progressive. Because of this, the intended
cumulative dose was not achieved. The other patient had
MEN-1 syndrome and had Cushing’s syndrome due to
ectopic ACTH production for which he underwent bilateral
adrenalectomy. Disease status at baseline was not known.
He had SD after treatment. TTP was 17 months.
Therapeutic effects are summarised in Table 3. Con-
sidering all 16 patients, response rate was 50%. This
includes 6% CR, 31% PR and 13% MR. SD was present
in 31% and PD in 19%. In the total group of GEP NETs,
overall response rate was 47% (2% CR, 26% PR, 19%
MR), SD was present in 35% and PD in 18% [14]. This
difference was not statistically significant (Fisher’s exact
test, p>0.05).
Discussion
The purpose of the present study was to evaluate whether
results of peptide receptor radionuclide therapy (PRRT)
with 177Lu-octreotate in patients with foregut carcinoid
tumours are different from those in patients from the total
group of gastroenteropancreatic neuroendocrine tumours
(GEP NETs). This is because foregut carcinoids are of a
different embryological origin than other GEP NETs and
survival of patients with metastasised foregut carcinoids is
shorter compared to patients with metastasised midgut
carcinoids [17]. The results of the present study indicate
that the overall tumour response rates with 177Lu-octreotate
treatment in the studied foregut carcinoids are comparable
Fig. 1 Treatment response with
177Lu-octreotate in a patient
with a metastasised bronchial
carcinoid (H heart, S stomach).
a Scintigraphy 24 h after the
first dose of 177Lu-octreotate
(left panel) and MRI 6 weeks
before starting treatment (right
panel): the arrowhead indicates
one of multiple liver metastases.
b Scintigraphy 24 h after the last
dose of 177Lu-octreotate (left
panel): the arrowhead indicates
decrease in uptake in one of the
liver metastases. MRI 5 months
after finishing the treatment
(right panel) visualises tumour
regression (arrowhead)
Fig. 2 Effects of therapy with
177Lu-octreotate in groups of
carcinoid tumours in relation to
disease status before treatment.
CR complete remission, MR
minor response, PD progressive
disease, PR partial remission,
SD stable disease
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to those in the whole group of GEP NETs. In foregut
carcinoids of bronchial, gastric or thymic origin, overall
response rate was 50%. In the total group of GEP NETs, the
overall response rate was 47% [14]. This difference was not
statistically significant. Especially patients with bronchial
carcinoids can respond well to treatment with 177Lu-
octreotate: tumour regression was achieved in six of nine
patients. There was no significant difference in treatment
outcome between atypical and typical bronchial carcinoids.
In gastric carcinoids, two out of five patients had tumour
regression, including one with a CR. All patients had type 3
gastric carcinoids, which tend to behave more aggressively
than other types. The role of treatment with 177Lu-
octreotate in thymic carcinoid is not yet clear, since only
two patients were treated: one had progression and one had
stable disease for 17 months. Certainly more patients with
bronchial, gastric and thymic carcinoids have to be
included in our study to determine the effect of 177Lu-
octreotate in this group more precisely.
A previous study in GEP NET patients demonstrated a
positive correlation between high tumour uptake on pre-
therapy SRS and high remission rates [14]. In that study,
also patients with rather low tumour uptake on pre-therapy
SRS were studied, i.e. tumour uptake equal to normal liver
uptake (grade 2). In the present study, however, all patients
had tumour uptake that was higher than liver uptake on pre-
therapy SRS (grade 3 or 4), and this could explain why
results in foregut carcinoids are comparable to those in the
whole group of carcinoids, despite their more aggressive
behaviour. However, since in the study of Kwekkeboom et
al. [14] only 4 of 125 patients (3%) had grade 2 uptake, the
lack of patients with grade 2 uptake in the present study
probably affected the present results only mildly or not at
all. On the other hand, in the present study only one patient
Fig. 3 Treatment response with
177Lu-octreotate in a patient
with a metastasised gastric car-
cinoid. a Scintigraphy 24 h after
the first dose of 177Lu-octreotate
(left panel) demonstrates multi-
ple metastases in the abdomen
(arrowheads). CT 6 weeks be-
fore starting treatment (right
panel) visualises a lymph node
metastasis between the aorta and
inferior vena cava (arrow). b
Scintigraphy 24 h after the last
dose of 177Lu-octreotate (left
panel) demonstrates that patho-
logical uptake in the abdomen
has disappeared. CT 5 months
after finishing the treatment
(right panel) can no longer
visualise the lymph node
(arrow)
Table 3 Tumour responses
in 16 patients with foregut
carcinoids treated with
177Lu-octreotate
Values are n, with % in
parentheses
CR complete remission,
PR partial remission, MR
minor response, SD stable dis-









CR – 1 (20) – 1 (6)
PR 5 (56) – – 5 (31)
MR 1 (11) 1 (20) – 2 (13)
SD 2 (22) 2 (40) 1 (50) 5 (31)
PD 1 (11) 1 (20) 1 (50) 3 (19)
CR + PR + MR 6 (67) 2 (40) – 8 (50)
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(6%) had grade 4 uptake (tumour uptake much more than
normal liver uptake), whereas 19% of patients in the total
group of GEP NETs had grade 4 uptake. These differences
in tumour uptake on pre-therapy SRS were not statistically
significant.
The study in the total group of GEP NETs demonstrated
some factors that predict a higher chance of progressive
disease despite the treatment with 177Lu-octreotate [14].
These factors were: high tumour mass, extensive liver
metastases, weight loss and low KPS. Since the difference
in the frequencies of these factors is not statistically
significant, the role of these factors is limited when
comparing the results of therapy in patients with the studied
foregut carcinoid tumours and those in patients from the
total group of GEP NETs. The observed remission rates are
therefore reliably comparable.
Although remission rates in patients with the studied
foregut carcinoids are comparable to those in patients with
other GEP NETs, our study suggests that median TTP is
shorter. We found a median TTP of 31 months in bronchial
carcinoids (range of duration of follow-up 9–34 months,
median 20.5 months), which is less than the median TTP of
more than 36 months in the group of all GEP NETs (range
of duration of follow-up 7–44 months, median 16 months)
[14]. In gastric carcinoids the estimated TTP was
16 months; however, the group was very small (n=4) and
in two patients TTP was not yet known. This possibly
shorter median TTP is not unexpected, since epidemiolog-
ical research indicates a shorter survival for metastasised
bronchopulmonary carcinoids compared with the total
group of metastasised carcinoids. The Surveillance Epide-
miology and End Results (SEER) database reports a 5-year
survival of 38.5% in patients with distant metastases from
any primary carcinoid site, whereas it is limited to 25.6% in
patients with metastasised bronchial carcinoid [17]. It is of
note that 5-year survival in patients with metastasised
gastric carcinoids is 21.2% [17].
It is important to realise that all patients in the present
study had tumours with strong expression of somatostatin
receptors (sst): tumour uptake on SRS was higher than
normal liver tissue in all patients. A study on expression of
sst subtype 2 (sst2) in neuroendocrine tumours of the lung
suggested that sst2 mRNA content is related to the degree
of tumour differentiation [18]. This may imply that the
treated patients in the study all had relatively well
differentiated tumours, whereas epidemiological databases
about survival include poorly differentiated tumours as
well. Hence, the treatment results obtained in this study are
not valid for the total group of patients with foregut
carcinoids. To our knowledge, no data are available about
what proportion of all patients with bronchial, gastric or
thymic carcinoids has low or absent somatostatin receptor
expression and what proportion would therefore not be
eligible for the treatment with 177Lu-octreotate.
Comparison of 177Lu-octreotate treatment in patients
with metastasised foregut carcinoid tumours with other
treatment modalities is difficult, as specific data are scarce.
Kwekkeboom et al. provided an overview of results of
several chemotherapy regimens in the total group of GEP
NETs, including carcinoids. Treatment with 177Lu-octreo-
tate performed better than these regimens, especially when
considering TTP [see 14 for in-depth comparison]. Granberg
et al. [19] reported their experience in treating patients
with bronchial carcinoids. Biotherapy resulted in symptom-
Table 4 Overview of results of peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide and [111In-DTPA0]octreotide in patients
with foregut carcinoid tumours
Study Radiolabelled peptide Cum. dose Carcinoid origin PD at start Outcome (TTP)
Otte et al. [22] 90Y-DOTATOC 4.8–8.9 GBq/m2 3 Thymus NA 2 SD, 1 PD
1 Duodenum NA 1 SD
Waldherr et al. [23] 90Y-DOTATOC 6.0 GBq/m2 7 Bronchus 7 1 CR, 1 PR, 5 SD
Waldherr et al. [24] 90Y-DOTATOC 7.4 GBq/m2 3 Bronchus 3 3 SD
Bodei et al. [25] 90Y-DOTATOC 5.92–11.1 GBq 2 Bronchus NA 1 PR (3 mo), 1 SD (13 mo)
1 Stomach NA 1 SD (10 mo)
Valkema et al. [26]a 90Y-DOTATOC 5.1–32.6 GBq 2 Bronchus 2 2 PD
2 Stomach 2 2 PD
1 Thymus 1 1 SD
Anthony et al. [27] [111In-DTPA0]octreotide 13.3–26.6 GBq 4 Foregutb NA 1 PR, 3 SD
Valkema et al. [28]a [111In-DTPA0]octreotide 40.5–58.0 GBq 3 Bronchus 3 2 SD, 1 PD
1 Otherc 1 1 MR
90 Y-DOTATOC [90 Y-DOTA0 ,Tyr3 ]octreotide, CR complete remission, MR minor response, NA not available, PD progressive disease, PR partial
remission, SD stable disease, TTP time to progression
a Additional data obtained from original study database
b Not further specified
c Presumably derived from mucosa of sphenoid sinus
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atic improvement of carcinoid syndrome in 7 of 16 patients.
Anti-proliferative effects, however, were limited as disease
progressed in 21 of 25 patients. Best results with chemo-
therapy were achieved with cisplatin/etoposide: two of eight
patients had an objective response and one had stable
disease. TTP was limited (7 months). With other chemo-
therapy regimens, no objective response was reported and
maximum response duration was 12 months in a patient
treated with streptozotocin/5-fluorouracil. Those results are
less favourable than the results with 177Lu-octreotate. We
therefore think that 177Lu-octreotate could be considered if
somatostatin analogues (or interferon) fails and tumour
uptake on SRS is grade 2 or more.
Peptide receptor radionuclide therapy is also possible
with radiolabelled somatostatin analogues other than 177Lu-
octreotate, e.g. 111In-octreotide and [90Y-DOTA0,Tyr3]
octreotide (90Y-DOTATOC). The mentioned radionuclides
have distinct physical properties. 111In emits Auger elec-
trons and γ-rays. The Auger electrons have a maximum
penetration range in tissue of 10 μm. 90Y is a β-emitter
with a maximum penetration range in tissue of 12 mm and
177Lu is a β-emitter with a maximum particle range in
tissue of 2 mm. It also emits γ-rays, which allows imaging
and dosimetry [20]. These differences in particle range
might have therapeutic consequences in the future as most
patients have tumours of various sizes. In a study in
animals with various tumour sizes, therapy with both 90Y-
and 177Lu-labelled octreotate yielded better remission rates
than therapy with either 90Y- or 177Lu-labelled octreotate
alone [21]. However, a benefit of the combination of 90Y-
octreotate and 177Lu-octreotate in patients has not been
confirmed, because a randomised clinical trial is lacking.
Table 4 provides an overview of results of treatment with
111In-octreotide and 90Y-DOTATOC [22–28] in patients
with foregut carcinoid tumours. In this overview, the study
with the largest number of patients reported tumour
remission in two (1 CR, 1 PR) and stable disease in five
out of seven patients with progressive, bronchial carcinoids.
Specific data on TTP for patients with foregut carcinoids
are lacking in most of these studies (Table 4). In general,
results of treatment with 177Lu-octreotate in foregut
carcinoid tumours in terms of tumour regression seem
favourable compared to treatment with 111In-octreotide and
90Y-DOTATOC. This may be partly because of the higher
affinity of [DOTA0,Tyr3]octreotate compared with [DOTA0,
Tyr3]octreotide for sst2 [29], which is the most frequently
expressed subtype on GEP NETs [30] and certainly because
the physical properties of 177Lu are better suited for therapy
than those of 111In when labelled to a somatostatin
analogue. However, comparison of these other treatments
with treatment using 177Lu-octreotate is difficult. The
number of studied patients was small in all reports.
Different inclusion criteria were used and the patient
conditions at baseline may have varied. Response criteria
may have differed, and some reports had dose escalation as
their purpose and therefore some patients had a relatively
low cumulative dose [see 31 for in-depth comparison].
In conclusion, 177Lu-octreotate treatment can be effec-
tive in patients with sst2-positive bronchial and gastric
carcinoids. Its role in thymic carcinoids cannot be deter-
mined yet because of the limited number of patients. The
overall remission rate of 50% in patients with foregut
carcinoids of bronchial, gastric and thymic origin is
comparable with that in the total group of gastroentero-
pancreatic neuroendocrine tumours.
References
1. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij
PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-
DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experi-
ence with more than 1000 patients. Eur J Nucl Med 1993;20:716–
31.
2. Williams ED, Sandler M. The classification of carcinoid tumours.
Lancet 1963;1:238–9.
3. Crocetti E, Paci E. Malignant carcinoids in the USA, SEER 1992–
1999. An epidemiological study with 6830 cases. Eur J Cancer
Prev 2003;12:191–4.
4. Rindi G, Capella C, Solcia E. Introduction to a revised
clinicopathological classification of neuroendocrine tumors of
the gastroenteropancreatic tract. Q J Nucl Med 2000;44:13–21.
5. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The
new World Health Organization classification of lung tumours.
Eur Respir J 2001;18:1059–68.
6. Skuladottir H, Olsen JH, Hirsch FR. Incidence of lung cancer in
Denmark: historical and actual status. Lung Cancer 2000;27:107–
18.
7. Pareja E, Arnau A, Artigues E, Peiro F, Hostalet F, Martin E, et al.
Tumores carcinoides bronquiales: un estudio prospectivo. Arch
Bronconeumol 1998;34:71–5.
8. Soga J, Yakuwa Y. Bronchopulmonary carcinoids: an analysis of
1,875 reported cases with special reference to a comparison
between typical carcinoids and atypical varieties. Ann Thorac
Cardiovasc Surg 1999;5:211–9.
9. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three
subtypes of gastric argyrophil carcinoid and the gastric neuroen-
docrine carcinoma: a clinicopathologic study. Gastroenterology
1993;104:994–1006.
10. Mulkeen A, Cha C. Gastric carcinoid. Curr Opin Oncol
2005;17:1–6.
11. Delle Fave G, Capurso G, Milione M, Panzuto F. Endocrine
tumours of the stomach. Best Pract Res Clin Gastroenterol
2005;19:659–73.
12. Soga J, Yakuwa Y, Osaka M. Evaluation of 342 cases of
mediastinal/thymic carcinoids collected from literature: a compar-
ative study between typical carcinoids and atypical varieties. Ann
Thorac Cardiovasc Surg 1999;5:285–92.
13. Fukai I, Masaoka A, Fujii Y, Yamakawa Y, Yokoyama T, Murase
T, et al. Thymic neuroendocrine tumor (thymic carcinoid): a
clinicopathologic study in 15 patients. Ann Thorac Surg
1999;67:208–11.
14. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder
WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-
1226 Eur J Nucl Med Mol Imaging (2007) 34:1219–1227
DOTA0,Tyr3]octreotate in patients with endocrine gastroentero-
pancreatic tumors. J Clin Oncol 2005;23:2754–62.
15. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW,
Srinivasan A, Erion JL, et al. [177Lu-DOTA0Tyr3]octreotate:
comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl
Med 2001;28:1319–25.
16. Green S, Weiss GR. Southwest Oncology Group standard
response criteria, endpoint definitions and toxicity criteria. Invest
New Drugs 1992;10:239–53.
17. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715
carcinoid tumors. Cancer 2003;97:934–59.
18. Papotti M, Croce S, Macri L, Funaro A, Pecchioni C, Schindler
M, et al. Correlative immunohistochemical and reverse transcrip-
tase polymerase chain reaction analysis of somatostatin receptor
type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol
2000;9:47–57.
19. Granberg D, Eriksson B, Wilander E, Grimfjard P, Fjallskog ML,
Oberg K, et al. Experience in treatment of metastatic pulmonary
carcinoid tumors. Ann Oncol 2001;12:1383–91.
20. Teunissen JJ, Kwekkeboom DJ, de Jong M, Esser JP, Valkema R,
Krenning EP. Endocrine tumours of the gastrointestinal tract.
Peptide receptor radionuclide therapy. Best Pract Res Clin
Gastroenterol 2005;19:595–616.
21. De Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP.
Combination radionuclide therapy using 177Lu- and 90Y-labeled
somatostatin analogs. J Nucl Med 2005;46 Suppl 1:13S–7S.
22. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P,
et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med
1999;26:1439–47.
23. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand
J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-
DOTATOC) in the treatment of neuroendocrine tumours: a clinical
phase II study. Ann Oncol 2001;12:941–5.
24. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A,
Nitzsche EU, et al. Tumor response and clinical benefit in
neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl
Med 2002;43:610–6.
25. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca
P, et al. Receptor-mediated radionuclide therapy with 90Y-
DOTATOC in association with amino acid infusion: a phase I
study. Eur J Nucl Med Mol Imaging 2003;30:207–16.
26. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker
WH, et al. Survival and response after peptide receptor radionu-
clide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with
advanced gastroenteropancreatic neuroendocrine tumors. Semin
Nucl Med 2006;36:147–56.
27. Anthony LB, Woltering EA, Espanan GD, Cronin MD, Maloney
TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in
gastroenteropancreatic malignancies. Semin Nucl Med
2002;32:123–32.
28. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP,
Lugtenburg PJ, et al. Phase I study of peptide receptor
radionuclide therapy with [111In-DTPA0]octreotide: the Rotterdam
experience. Semin Nucl Med 2002;32:110–22.
29. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS,
et al. Affinity profiles for human somatostatin receptor subtypes
SST1–SST5 of somatostatin radiotracers selected for scintigraphic
and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.
30. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor
sst1–sst5 expression in normal and neoplastic human tissues using
receptor autoradiography with subtype-selective ligands. Eur J
Nucl Med 2001;28:836–46.
31. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB,
Pauwels S, Kvols LK, et al. Overview of results of peptide
receptor radionuclide therapy with 3 radiolabeled somatostatin
analogs. J Nucl Med 2005;46:62S–6S.
Eur J Nucl Med Mol Imaging (2007) 34:1219–1227 1227
